AIM ImmunoTech announced that the final patient has received the first dose in its Phase 2 DURIPANC trial, testing Ampligen combined with AstraZeneca's Imfinzi for metastatic pancreatic cancer. The trial's primary endpoint is Clinical Benefit Rate at 24 weeks, with topline results expected in Q1 2027. Secondary analyses, including overall survival and immune profiling, will begin mid-2027 to help design a pivotal Phase 3 trial. Positive earlier data suggest Ampligen may improve survival and quality of life in certain biomarker-defined patient groups, supporting a personalized treatment approach.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Ethereum rose 3.17% to $1,923.53, outperforming Bitcoin's modest 0.18% gain to $64,588.87, signaling an early rotation toward large-cap altcoins. Despite this, overall market activity slowed, with declines in DeFi, stablecoin, and derivatives trading...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
A Gaza resident raised over £55,000 on GoFundMe to support his family but faced issues as the platform cannot pay directly to Gaza, forcing funds through intermediaries who failed to deliver the full amount. This highlights a broader problem in human...
Crypto investigator ZachXBT criticized all current hardware wallets as insecure and unreliable for signing transactions or storing significant funds. He highlighted Ledger as particularly problematic due to frequent updates that disrupt basic functio...
